Stagnant revenues for Pfizer this quarter

Pfizer sales flat at $11.97 billion, as profits triple on last year's huge Exubera discontinuation charge. Adjusted EPS would be 62 cents this year, up from 58 cents in 2007. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.